Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anti-CD30 antibody-based therapy.

H B Koon1, R P Junghans

  • 1Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.

Current Opinion in Oncology
|November 21, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases.

Cancer gene therapy·2016
Same author

Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery.

Cancer gene therapy·2016
Same author

Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases.

Cancer gene therapy·2014
Same author

Dystrophia myotonia: why focus on foci?

European journal of human genetics : EJHG·2009
Same author

Sorting vector producer cells for high transgene expression increases retroviral titer.

Journal of virological methods·2008
Same author

Chimeric immune receptors (CIRs) specific to JC virus for immunotherapy in progressive multifocal leukoencephalopathy (PML).

International immunology·2007

Antibody-based therapies targeting CD30 show promise for treating CD30+ neoplasms. These therapies leverage CD30's specific expression on cancer cells for targeted treatment, offering new therapeutic options.

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • CD30 is highly expressed on certain cancer cells but minimally on normal tissues.
  • This differential expression makes CD30 an attractive target for cancer therapies.
  • Anti-CD30 antibodies have demonstrated potential in modulating immune responses and delivering therapeutic payloads.

Purpose of the Study:

  • To review the therapeutic potential of anti-CD30 antibodies and related conjugates.
  • To evaluate anti-CD30-based strategies for treating CD30-positive neoplasms.
  • To summarize recent preclinical and clinical findings on anti-CD30 therapies.

Main Methods:

  • Review of preclinical and clinical studies involving anti-CD30 antibodies.
  • Analysis of various anti-CD30 therapeutic formats including bispecific antibodies, immunotoxins, and radioimmunoconjugates.

Related Experiment Videos

  • Evaluation of CD30 expression patterns in neoplasms versus normal tissues.

    • Main Results:

    • Anti-CD30 antibodies function as signaling molecules and immune system modulators.
    • Preclinical and clinical investigations show efficacy of various anti-CD30 constructs.
    • Therapeutic strategies include unmodified antibodies, bispecific antibodies, immunotoxins, and radioimmunoconjugates.

    Conclusions:

    • Anti-CD30-based therapies represent a promising new class of treatments for CD30+ cancers.
    • Targeting CD30 offers a viable strategy for developing novel cancer therapeutics.
    • Further clinical development is warranted for these promising anti-CD30-based modalities.